Compare Abbott Laboratories (ABT) vs MakeMyTrip Ltd (MMYT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs MakeMyTrip Ltd — how do they compare? Abbott Laboratories trades at $95.4 (market cap $166.94B), while MakeMyTrip Ltd trades at $56.17 (market cap $5.57B). The key difference: Abbott Laboratories is far larger — about 30× MakeMyTrip Ltd's market cap, and Abbott Laboratories pays a 2.63% dividend while MakeMyTrip Ltd pays none. Which is the better fit depends on your goals.
| ABT | MMYT | |
|---|---|---|
Market Cap | $166.94B | $5.57B |
Sector | Health | Technology |
52-Week High | $136.62 | $103.21 |
52-Week Low | $82.57 | $36.30 |
Enterprise Value | $193.69B | $6.21B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
MakeMyTrip (MMYT) trades at $57.35, down 1.58% today but showing strong technical momentum with bullish moving averages. The company demonstrates robust fundamentals with Q1 2026 EPS beating expectations at $0.25 versus $0.1654, continuing a trend of earnings outperformance. Revenue reached $978.34M in 2025 with healthy 73.77% gross margins, though valuation metrics appear elevated with a P/E of 159.17. Analyst sentiment remains strongly positive with 72.73% buy ratings.
The outlook remains favorable given consistent earnings beats and strong travel demand recovery, though high valuation multiples and rising debt-to-asset ratios from 12.13% to 80.57% projected for 2026 present significant risks. Temporary travel disruptions have pressured growth, but platform resilience across hotel and package segments supports the bullish case. Investors should weigh growth potential against valuation concerns and increasing leverage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About MakeMyTrip Ltd
MakeMyTrip Ltd. is a leading online travel company in India, providing a comprehensive range of travel services and products, including air tickets, hotels, holiday packages, rail tickets, and bus tickets. The company operates its primary websites and mobile apps under the brands MakeMyTrip, Goibibo, and RedBus. MMYT serves as a key intermediary in India's fragmented travel market, leveraging its platform to offer convenience and competitive pricing to consumers and businesses.
Read more on MMYT →
